Chemotherapy combinated with ADSCs genetically engineered to express human carboxylesterase-2, can overcome drug resistance and exhibit survival benefits in ovarian cancer with intraperitoneal metastasis [43]. Here, CES2 is linked to ovarian carcinoma.